- Biotech Prothena scraps lead drug following mid-stage study failure
- First Opinion Using Air Force ‘boldface’ to ease the opioid crisis
- First Opinion On drug pricing, Trump could rely on bluster and bad ideas. But there’s a better alternative
- Biotech Startup unwinds the role of chromatin to target epigenetic changes in cancer
- First Opinion 3 ways to expand access to mental health care beyond adding more psychiatrists
- Health The vaccine dilemma: How experts weigh benefits for many against risks for a few
- Special Report The next generation of doctors may be learning bad habits at teaching hospitals with many safety violations
- Politics With a new slate of appointees, Trump’s FTC expected to take tough stand on drug industry
-
- Biotech Prothena scraps lead drug following mid-stage study failure
- First Opinion Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay
